Targeting CD70 for Human Therapeutic Use

  • Tamar E. Boursalian
  • Julie A. McEarchern
  • Che-Leung Law
  • Iqbal S. Grewal
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 647)


Expression of CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Antibody blockade of CD70-CD27 interaction inhibits the onset of experimental autoimmune encephalomyelits and cardiac allograft rejection in mice. CD70 has been also detected on hematological tumors and on carcinomas. The highly restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies as well as its potential role in autoimmune and inflammatory conditions makes it an attractive target for antibody-based therapeutics. This chapter provides an overview of the physiological role of CD70-CD27 interactions and discusses various approaches to target this pathway for therapeutic use in cancers and autoimmunity.


Renal Cell Carcinoma CD70 Expression Systemic Lupus Erythematosis Patient Thymic Carcinoma Experimental Autoimmune Encephalitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994; 76:959–62.PubMedCrossRefGoogle Scholar
  2. 2.
    Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85:3378–404.PubMedGoogle Scholar
  3. 3.
    Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3:745–56.PubMedCrossRefGoogle Scholar
  4. 4.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487–501.PubMedCrossRefGoogle Scholar
  5. 5.
    Renshaw BR, Fanslow WC 3rd, Armitage RJ et al. Humoral immune responses in CD40 ligand-deficient mice. J Exp Med 1994; 180:1889–900.PubMedCrossRefGoogle Scholar
  6. 6.
    Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 1998; 187:1825–38.PubMedCrossRefGoogle Scholar
  7. 7.
    Gulino AV, Notarangelo LD. Hyper IgM syndromes. Curr Opin Rheumatol 2003; 15:422–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Goodwin RG, Alderson MR, Smith CA et al. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 1993; 73:447–56.PubMedCrossRefGoogle Scholar
  9. 9.
    Bowman MR, Crimmins MA, Yetz-Aldape J et al. The cloning of CD70 and its identification as the ligand for CD27. J Immunol 1994; 152:1756–61.PubMedGoogle Scholar
  10. 10.
    Peitsch MC, Tschopp J. Comparative molecular modelling of the Fas-ligand and other members of the TNF family. Mol Immunol 1995; 32:761–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Bossen C, Ingold K, Tardivel A et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 2006; 281:13964–71.PubMedCrossRefGoogle Scholar
  12. 12.
    Camerini D, Walz G, Loenen WA et al. The T-cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol 1991; 147:3165–9.PubMedGoogle Scholar
  13. 13.
    Hintzen RQ, van Lier RA, Kuijpers KC et al. Elevated levels of a soluble form of the T-cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 1991; 35:211–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Akiba H, Nakano H, Nishinaka S et al. CD27, a member of the tumor necrosis factor receptor super-family, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5 and NF-kappaB-inducing kinase. J Biol Chem 1998; 273:13353–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity 2004; 21:477–89.PubMedCrossRefGoogle Scholar
  16. 16.
    Prasad KV, Ao Z, Yoon Y et al. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc Natl Acad Sci USA 1997; 94:6346–51.PubMedCrossRefGoogle Scholar
  17. 17.
    Hintzen RQ, Lens SM, Koopman G et al. CD70 represents the human ligand for CD27. Int Immunol 1994; 6:477–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Lens SM, de Jong R, Hooibrink B et al. Phenotype and function of human B-cells expressing CD70 (CD27 ligand). Eur J Immunol 1996; 26:2964–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Lens SM, Baars PA, Hooibrink B et al. Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T-cells. Immunology 1997; 90:38–45.PubMedCrossRefGoogle Scholar
  20. 20.
    Akiba H, Miyahira Y, Atsuta M et al. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J Exp Med 2000; 191:375–80.PubMedCrossRefGoogle Scholar
  21. 21.
    Tesselaar K, Xiao Y, Arens R et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol 2003; 170:33–40.PubMedGoogle Scholar
  22. 22.
    Bullock TN, Yagita H. Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8 + T-cell responses in the absence of CD4 + T-cells. J Immunol 2005; 174:710–7.PubMedGoogle Scholar
  23. 23.
    Hishima T, Fukayama M, Hayashi Y et al. CD70 expression in thymic carcinoma. Am J Surg Pathol 2000; 24:742–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Hintzen RQ, Lens SM, Beckmann MP et al. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol 1994; 152:1762–73.PubMedGoogle Scholar
  25. 25.
    Hintzen RQ, de Jong R, Lens SM et al. CD27: marker and mediator of T-cell activation? Immunol Today 1994; 15:307–11.PubMedCrossRefGoogle Scholar
  26. 26.
    Lens SM, Tesselaar K, van Oers MH et al. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 1998; 10:491–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T-cell and B-cell activation. Curr Opin Immunol 2005; 17:275–81.PubMedCrossRefGoogle Scholar
  28. 28.
    de Jong R, Loenen WA, Brouwer M et al. Regulation of expression of CD27, a T-cell-specific member of a novel family of membrane receptors. J Immunol 1991; 146:2488–94.PubMedGoogle Scholar
  29. 29.
    Hintzen RQ, de Jong R, Lens SM et al. Regulation of CD27 expression on subsets of mature T-lymphocytes. J Immunol 1993; 151:2426–35.PubMedGoogle Scholar
  30. 30.
    van Lier RA, Borst J, Vroom TM et al. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T-cell differentiation antigen. J Immunol 1987; 139:1589–96.PubMedGoogle Scholar
  31. 31.
    Watts TH. TNF/TNFR family members in costimulation of T-cell responses. Annu Rev Immunol 2005; 23:23–68.PubMedCrossRefGoogle Scholar
  32. 32.
    Jacquot S, Kobata T, Iwata S et al. CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T-cell-dependent B-cell responses: enhancement of plasma cell differentiation by CD27 signaling. J Immunol 1997; 159:2652–7.PubMedGoogle Scholar
  33. 33.
    Kobata T, Jacquot S, Kozlowski S et al. CD27-CD70 interactions regulate B-cell activation by T-cells. Proc Natl Acad Sci USA 1995; 92:11249–53.PubMedCrossRefGoogle Scholar
  34. 34.
    Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+peripheral blood B-cells expressing the CD27 cell surface antigen carry so matically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B-cells. J Exp Med 1998; 188:1679–89.PubMedCrossRefGoogle Scholar
  35. 35.
    Hendriks J, Gravestein LA, Tesselaar K et al. CD27 is required for generation and long-term maintenance of T-cell immunity. Nat Immunol 2000; 1:433–40.PubMedCrossRefGoogle Scholar
  36. 36.
    Sugita K, Hirose T, Rothstein DM et al. CD27, a member of the nerve growth factor receptor family, is preferentially expressed on CD45RA+CD4 T-cell clones and involved in distinct immunoregulatory functions. J Immunol 1992; 149:3208–16.PubMedGoogle Scholar
  37. 37.
    Hintzen RQ, Lens SM, Lammers K et al. Engagement of CD27 with its ligand CD70 provides a second signal for T-cell activation. J Immunol 1995; 154:2612–23.PubMedGoogle Scholar
  38. 38.
    Xiao Y, Hendriks J, Langerak P et al. CD27 is acquired by primed B-cells at the centroblast stage and promotes germinal center formation. J Immunol 2004; 172:7432–41.PubMedGoogle Scholar
  39. 39.
    Agematsu K, Nagumo H, Oguchi Y et al. Generation of plasma cells from peripheral blood memory B-cells: synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood 1998; 91:173–80.PubMedGoogle Scholar
  40. 40.
    Takeda K, Oshima H, Hayakawa Y et al. CD27-mediated activation of murine NK cells. J Immunol 2000; 164:1741–5.PubMedGoogle Scholar
  41. 41.
    Orengo AM, Cantoni C, Neglia F et al. Reciprocal expression of CD70 and of its receptor, CD27, in human long term-activated T-and natural killer (NK) cells: inverse regulation by cytokines and role in induction of cytotoxicity. Clin Exp Immunol 1997; 107:608–13.PubMedCrossRefGoogle Scholar
  42. 42.
    Arens R, Tesselaar K, Baars PA et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T-cells and results in IFNgamma-mediated B-cell depletion. Immunity 2001; 15:801–12.PubMedCrossRefGoogle Scholar
  43. 43.
    Arens R, Schepers K, Nolte MA et al. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+T-cell formation. J Exp Med 2004; 199:1595–605.PubMedCrossRefGoogle Scholar
  44. 44.
    Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T-cells and complements CD28 in generation and establishment of the effector T-cell pool. J Exp Med 2003; 198:1369–80.PubMedCrossRefGoogle Scholar
  45. 45.
    Nieland JD, Graus YF, Dortmans YE et al. CD40 and CD70 costimulate a potent in vivo antitumor T-cell response. J Immunother 1998; 21:225–36.PubMedCrossRefGoogle Scholar
  46. 46.
    Kelly JM, Darcy PK, Markby JL et al. Induction of tumor-specific T-cell memory by NK cell-mediated tumor rejection. Nat Immunol 2002; 3:83–90.PubMedCrossRefGoogle Scholar
  47. 47.
    Nakajima A, Oshima H, Nohara C et al. Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2000; 109:188–96.PubMedCrossRefGoogle Scholar
  48. 48.
    Aramaki O, Shirasugi N, Akiyama Y et al. CD27/CD70, CD134/CD134 ligand and CD30/CD153 pathways are independently essential for generation of regulatory cells after intratracheal delivery of alloantigen. Transplantation 2003; 76:772–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Hartwig UF, Karlsson L, Peterson PA et al. CD40 and IL-4 regulate murine CD27L expression. J Immunol 1997; 159:6000–8.PubMedGoogle Scholar
  50. 50.
    Laouar A, Haridas V, Vargas D et al. CD70+ antigen-presenting cells control the proliferation and differentiation of T-cells in the intestinal mucosa. Nat Immunol 2005; 6:698–706.PubMedCrossRefGoogle Scholar
  51. 51.
    Arens R, Nolte MA, Tesselaar K et al. Signaling through CD70 regulates B-cell activation and IgG production. J Immunol 2004; 173:3901–8.PubMedGoogle Scholar
  52. 52.
    Garcia P, De Heredia AB, Bellon T et al. Signalling via CD70, a member of the TNF family, regulates T-cell functions. J Leukoc Biol 2004; 76:263–70.PubMedCrossRefGoogle Scholar
  53. 53.
    Brugnoni D, Airo P, Marino R et al. CD70 expression on T-cell subpopulations: study of normal individuals and patients with chronic immune activation. Immunol Lett 1997; 55:99–104.PubMedCrossRefGoogle Scholar
  54. 54.
    Lee WW, Yang ZZ, Li G et al. Unchecked CD70 expression on T-cells lowers threshold for T-cell activation in rheumatoid arthritis. J Immunol 2007; 179:2609–15.PubMedGoogle Scholar
  55. 55.
    Oelke K, Lu Q, Richardson D et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T-cells and T-cells treated with DNA methylation inhibitors. Arthritis Rheum 2004; 50:1850–60.PubMedCrossRefGoogle Scholar
  56. 56.
    Han BK, White AM, Dao KH et al. Increased prevalence of activated CD70+ CD4+ T-cells in the periphery of patients with systemic lupus erythematosus. Lupus 2005; 14:598–606.PubMedCrossRefGoogle Scholar
  57. 57.
    Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T-cells and T-cells treated with lupus-inducing drugs. J Immunol 2005; 174:6212–9.PubMedGoogle Scholar
  58. 58.
    Sawalha AH, Richardson B. DNA methylation in the pathogenesis of systemic lupus erythematosus. Current Pharmacogenomics 2005; 3:73–8.CrossRefGoogle Scholar
  59. 59.
    Sawalha AH, Jeffries M. Defective DNA methylation and CD70 overexpression in CD4+ T-cells in MRL/lpr lupus-prone mice. Eur J Immunol 2007; 37:1407–13.PubMedCrossRefGoogle Scholar
  60. 60.
    Quddus J, Johnson KJ, Gavalchin J et al. Treating activated CD4+T-cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 1993; 92:38–53.PubMedCrossRefGoogle Scholar
  61. 61.
    Yung RL, Quddus J, Chrisp CE et al. Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 1995; 154:3025–35.PubMedGoogle Scholar
  62. 62.
    Manocha S, Rietdijk S, Laouar A et al. CD70 antibody therapy for the prevention and treatment of experimental inflammatory bowel disease (IBD). FASEB J 2008; 22:Abstract 859.10.Google Scholar
  63. 63.
    Korn T, Oukka M, Kuchroo V et al. Th 17 cells: effector T-cells with inflammatory properties. Semin Immunol 2007; 19:362–71.PubMedCrossRefGoogle Scholar
  64. 64.
    Iwamoto S, Iwai S, Tsujiyama K et al. TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J Immunol 2007; 179:1449–57.PubMedGoogle Scholar
  65. 65.
    Gruss HJ, Kadin ME. Pathophysiology of hodgkin’s disease: functional and molecular aspects. Baillieres Clin Haematol 1996; 9:417–46.PubMedCrossRefGoogle Scholar
  66. 66.
    Lens SM, Drillenburg P, den Drijver BF et al. Aberrant expression and reverse signalling of CD70 on malignant B-cells. Br J Haematol 1999; 106:491–503.PubMedCrossRefGoogle Scholar
  67. 67.
    McEarchern JA, Smith LM, McDonagh CF et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. 2008; Manuscript submittedGoogle Scholar
  68. 68.
    Ho AW, Hatjiharissi E, Ciccarelli BT et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom’s Macroglobulinemia. Blood 2008Google Scholar
  69. 69.
    Lens SM, Keehnen RM, van Oers MH et al. Identification of a novel subpopulation of germinal center B-cells characterized by expression of IgD and CD70. Eur J Immunol 1996; 26:1007–11.PubMedCrossRefGoogle Scholar
  70. 70.
    Bahler DW, Levy R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc Natl Acad Sci USA 1992; 89:6770–4.PubMedCrossRefGoogle Scholar
  71. 71.
    Bahler DW, Zelenetz AD, Chen TT et al. Antigen selection in human lymphomagenesis. Cancer Res 1992; 52:5547s–5551s.PubMedGoogle Scholar
  72. 72.
    Yang ZZ, Novak AJ, Ziesmer SC et al. CD70+ nonHodgkin lymphoma B-cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T-cells. Blood 2007; 110:2537–44.PubMedCrossRefGoogle Scholar
  73. 73.
    Tournilhac O, Santos DD, Xu L et al. Mast cells in Waldenstrom’s macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006; 17:1275–82.PubMedCrossRefGoogle Scholar
  74. 74.
    Nilsson A, de Milito A, Mowafi F et al. Expression of CD27-CD70 on early B-cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. Exp Hematol 2005; 33:1500–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Agathanggelou A, Niedobitek G, Chen R et al. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol 1995; 147:1152–60.PubMedGoogle Scholar
  76. 76.
    Junker K, Hindermann W, von Eggeling F et al. CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol 2005; 173:2150–3.PubMedCrossRefGoogle Scholar
  77. 77.
    Diegmann J, Junker K, Gerstmayer B et al. Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry. Eur J Cancer 2005; 41:1794–801.PubMedCrossRefGoogle Scholar
  78. 78.
    Law CL, Gordon KA, Toki BE et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 2006; 66:2328–37.PubMedCrossRefGoogle Scholar
  79. 79.
    Held-Feindt J, Mentlein R. CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors. Int J Cancer 2002; 98:352–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Wischhusen J, Jung G, Radovanovic I et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 2002; 62:2592–9.PubMedGoogle Scholar
  81. 81.
    Aggarwal S, He T, Fitzhugh W et al. Membrane proteomic analyses of ovarian cancer identifies the immune modulators CD70 and B7-H2 as candidate markers of cisplatin response. Proceedings of the 99th Annual Meeting for the American Association for Cancer Research 2008; Abstract 2430.Google Scholar
  82. 82.
    Chahlavi A, Rayman P, Richmond AL et al. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res 2005; 65:5428–38.PubMedCrossRefGoogle Scholar
  83. 83.
    Diegmann J, Junker K, Loncarevic IF et al. Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia 2006; 8:933–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Smyth GP, Stapleton PP, Barden CB et al. Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells. Ann Surg Oncol 2003; 10:455–62.PubMedCrossRefGoogle Scholar
  85. 85.
    Aulwurm S, Wischhusen J, Friese M et al. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. Int J Cancer 2006; 118:1728–35.PubMedCrossRefGoogle Scholar
  86. 86.
    McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825–33.PubMedGoogle Scholar
  87. 87.
    Leonard JP, Link BK. Immunotherapy of non-Hodgkin’s lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hul D10 (apolizumab). Semin Oncol 2002; 29:81–6.PubMedCrossRefGoogle Scholar
  88. 88.
    Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100:768–73.PubMedCrossRefGoogle Scholar
  89. 89.
    Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: The opportunities and challenges. In: Grewal IS, ed. Therapeutic Targets of the TNF Superfamily. Austin: Landes Bioscience, 2008;8–36.Google Scholar
  90. 90.
    Miller RA, Maloney DG, Warnke R et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306:517–22.PubMedGoogle Scholar
  91. 91.
    Nishio M, Endo T, Fujimoto K et al. Persistent panhypogammaglobulinemia with selected loss of memory B-cells and impaired isotype expression after rituximab therapy for posttransplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol 2005; 75:527–9.PubMedCrossRefGoogle Scholar
  92. 92.
    van der Kolk LE, Baars JW, Prins MH et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100:2257–9.PubMedGoogle Scholar
  93. 93.
    Israel BF, Gulley M, Elmore S et al. Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas. Mol Cancer Ther 2005; 4:2037–44.PubMedCrossRefGoogle Scholar
  94. 94.
    Di Gaetano N, Cittera E, Nota R et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171:1581–7.PubMedGoogle Scholar
  95. 95.
    McEarchern JA, Oflazoglu E, Francisco L et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2007; 109:1185–92.PubMedCrossRefGoogle Scholar
  96. 96.
    Uchida J, Hamaguchi Y, Oliver JA et al. The innate mononuclear phagocyte network depletes B-lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659–69.PubMedCrossRefGoogle Scholar
  97. 97.
    Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B-cell immunotherapy. J Immunol 2005; 174:817–26.PubMedGoogle Scholar
  98. 98.
    Jeffrey SC, Andreyka JB, Bernhardt SX et al. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. Bioconjug Chem 2006; 17:831–40.PubMedCrossRefGoogle Scholar
  99. 99.
    Doronina SO, Mendelsohn BA, Bovee TD et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006; 17:114–24.PubMedCrossRefGoogle Scholar
  100. 100.
    Oflazoglu E, Stone IJ, Wood CG et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 2008; In Press.Google Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Tamar E. Boursalian
    • 1
  • Julie A. McEarchern
    • 1
  • Che-Leung Law
    • 1
  • Iqbal S. Grewal
    • 1
  1. 1.Department of Preclinical TherapeuticsSeattle Genetics, Inc.BothellUSA

Personalised recommendations